Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall

Objective: Pancreatic ductal adenocarcinoma is one of the most common causes of "peritoneal carcinomatosis" and has an insidious growth pattern. Thus, it falls into the differential diagnosis of other peritoneal malignancies including malignant mesothelioma. Recently, we have encountered a...

Full description

Bibliographic Details
Main Authors: Gokce ASKAN, Olca BASTURK
Format: Article
Language:English
Published: Federation of Turkish Pathology Societies 2021-05-01
Series:Türk Patoloji Dergisi
Subjects:
Online Access: http://www.turkjpath.org/pdf.php3?id=1955
_version_ 1797913639935541248
author Gokce ASKAN
Olca BASTURK
author_facet Gokce ASKAN
Olca BASTURK
author_sort Gokce ASKAN
collection DOAJ
description Objective: Pancreatic ductal adenocarcinoma is one of the most common causes of "peritoneal carcinomatosis" and has an insidious growth pattern. Thus, it falls into the differential diagnosis of other peritoneal malignancies including malignant mesothelioma. Recently, we have encountered an undifferentiated pancreatic carcinoma presenting with peritoneal disease and exhibiting immunoreactivity to calretinin, mimicking mesothelioma. In this study, we explored the incidence of calretinin expression in pancreatic ductal adenocarcinoma. Materials and Methods: Calretinin immunohistochemical staining was performed on the tissue microarrays (TMAs), which were created using three 0.6 mm diameter punches per tumor (n=113). Distribution and intensity of expression were evaluated. Results: The TMAs contained 86 well/moderately differentiated and 27 poorly differentiated/undifferentiated carcinomas. Calretinin was positive in nine tumors (8%); six with diffuse and strong staining, three with focal and/or weak staining. The incidence of calretinin expression was 15% in poorly differentiated/undifferentiated carcinomas (vs. 6% in well/moderately differentiated carcinomas, p=0.03). Conclusions: Pancreatic ductal adenocarcinomas, especially when poorly differentiated/undifferentiated, may be diffusely and strongly positive for calretinin creating a potential diagnostic challenge with malignant mesothelioma. Therefore, caution should be exercised when using this marker to explore a diagnosis of malignant mesothelioma. Tumors expressing calretinin without other mesothelial markers should prompt a careful evaluation of the morphologic and immunohistochemical features to exclude other malignancies. If the diagnosis of pancreatic ductal adenocarcinoma is considered, ductal differentiation can be demonstrated by using additional immunohistochemical markers such as mucin-related glycoproteins (MUC1, MUC5AC) and/or oncoproteins (CEA, B72.3, CA125).
first_indexed 2024-04-10T12:14:56Z
format Article
id doaj.art-b91970faaeee4a07b4843c92668205e6
institution Directory Open Access Journal
issn 1018-5615
1309-5730
language English
last_indexed 2024-04-10T12:14:56Z
publishDate 2021-05-01
publisher Federation of Turkish Pathology Societies
record_format Article
series Türk Patoloji Dergisi
spelling doaj.art-b91970faaeee4a07b4843c92668205e62023-02-15T16:15:50ZengFederation of Turkish Pathology SocietiesTürk Patoloji Dergisi1018-56151309-57302021-05-0137211512010.5146/tjpath.2020.01519Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic PitfallGokce ASKANOlca BASTURKObjective: Pancreatic ductal adenocarcinoma is one of the most common causes of "peritoneal carcinomatosis" and has an insidious growth pattern. Thus, it falls into the differential diagnosis of other peritoneal malignancies including malignant mesothelioma. Recently, we have encountered an undifferentiated pancreatic carcinoma presenting with peritoneal disease and exhibiting immunoreactivity to calretinin, mimicking mesothelioma. In this study, we explored the incidence of calretinin expression in pancreatic ductal adenocarcinoma. Materials and Methods: Calretinin immunohistochemical staining was performed on the tissue microarrays (TMAs), which were created using three 0.6 mm diameter punches per tumor (n=113). Distribution and intensity of expression were evaluated. Results: The TMAs contained 86 well/moderately differentiated and 27 poorly differentiated/undifferentiated carcinomas. Calretinin was positive in nine tumors (8%); six with diffuse and strong staining, three with focal and/or weak staining. The incidence of calretinin expression was 15% in poorly differentiated/undifferentiated carcinomas (vs. 6% in well/moderately differentiated carcinomas, p=0.03). Conclusions: Pancreatic ductal adenocarcinomas, especially when poorly differentiated/undifferentiated, may be diffusely and strongly positive for calretinin creating a potential diagnostic challenge with malignant mesothelioma. Therefore, caution should be exercised when using this marker to explore a diagnosis of malignant mesothelioma. Tumors expressing calretinin without other mesothelial markers should prompt a careful evaluation of the morphologic and immunohistochemical features to exclude other malignancies. If the diagnosis of pancreatic ductal adenocarcinoma is considered, ductal differentiation can be demonstrated by using additional immunohistochemical markers such as mucin-related glycoproteins (MUC1, MUC5AC) and/or oncoproteins (CEA, B72.3, CA125). http://www.turkjpath.org/pdf.php3?id=1955 calretininpancreatic ductal adenocarcinomapoorly differentiatedundifferentiatedmesothelioma
spellingShingle Gokce ASKAN
Olca BASTURK
Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
Türk Patoloji Dergisi
calretinin
pancreatic ductal adenocarcinoma
poorly differentiated
undifferentiated
mesothelioma
title Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
title_full Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
title_fullStr Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
title_full_unstemmed Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
title_short Expression of Calretinin, Marker of Mesothelial Differentiation, in Pancreatic Ductal Adenocarcinoma: A Potential Diagnostic Pitfall
title_sort expression of calretinin marker of mesothelial differentiation in pancreatic ductal adenocarcinoma a potential diagnostic pitfall
topic calretinin
pancreatic ductal adenocarcinoma
poorly differentiated
undifferentiated
mesothelioma
url http://www.turkjpath.org/pdf.php3?id=1955
work_keys_str_mv AT gokceaskan expressionofcalretininmarkerofmesothelialdifferentiationinpancreaticductaladenocarcinomaapotentialdiagnosticpitfall
AT olcabasturk expressionofcalretininmarkerofmesothelialdifferentiationinpancreaticductaladenocarcinomaapotentialdiagnosticpitfall